| Literature DB >> 23078060 |
Burcin Ekser1, Christopher Burlak, Joshua P Waldman, Andrew J Lutz, Leela L Paris, Massimiliano Veroux, Simon C Robson, Michael A Rees, David Ayares, Bruno Gridelli, A Joseph Tector, David Kc Cooper.
Abstract
Pigs are currently the preferred species for future organ xenotransplantation. With advances in the development of genetically modified pigs, clinical xenotransplantation is becoming closer to reality. In preclinical studies (pig-to-nonhuman primate), the xenotransplantation of livers from pigs transgenic for human CD55 or from α1,3-galactosyltransferase gene-knockout pigs+/- transgenic for human CD46, is associated with survival of approximately 7-9 days. Although hepatic function, including coagulation, has proved to be satisfactory, the immediate development of thrombocytopenia is very limiting for pig liver xenotransplantation even as a 'bridge' to allotransplantation. Current studies are directed to understand the immunobiology of platelet activation, aggregation and phagocytosis, in particular the interaction between platelets and liver sinusoidal endothelial cells, hepatocytes and Kupffer cells, toward identifying interventions that may enable clinical application.Entities:
Mesh:
Year: 2012 PMID: 23078060 PMCID: PMC3774271 DOI: 10.1586/eci.12.56
Source DB: PubMed Journal: Expert Rev Clin Immunol ISSN: 1744-666X Impact factor: 4.473